Tecan Group (TECN.SW) Stock Price
Tecan Group Price
Revenue has compounded at 4.2% per year over the past 19 years to 882.48 M CHF. Earnings per share have grown at 2.3% per year over the last 18 years. Tecan Group's net margin stands at -12.5%, down from 12.9% several years earlier. Tecan Group currently offers a dividend yield of about 0.63%. The dividend has grown at 6.5% per year over the past 19 years. Analysts set a median price target of 168.30 CHF, implying 29.0% below the current price. Of 13 analysts, 8 rate the stock a buy — an overall Buy consensus.
Tecan Group stock price
Tecan Group business model & stock analysis
Frequently asked questions about Tecan Group
The business model of Tecan Group AG revolves around the development, manufacturing, and distribution of laboratory automation and detection solutions. Tecan offers a wide range of products and services that cater to various scientific research, diagnostics, and drug discovery applications. By providing innovative and reliable laboratory instruments, Tecan aims to enhance efficiency, accuracy, and productivity in the life science industry. With a focus on automation, Tecan's solutions enable scientists and researchers to streamline their workflows, improve data quality, and ultimately accelerate the pace of scientific discoveries. Tecan Group AG is committed to driving advancements in laboratory automation and empowering its customers in their quest for scientific breakthroughs.
Tecan Group AG is primarily active in the life sciences and clinical diagnostics industries.
The main competitors of Tecan Group AG in the market include companies such as PerkinElmer, Thermo Fisher Scientific, Danaher Corporation, and BioTek Instruments Inc. These companies operate in the life sciences and diagnostics sector, offering similar products and solutions. With its innovative technologies and extensive product portfolio, Tecan Group AG competes with these industry leaders to provide laboratories and research facilities with advanced laboratory automation systems, liquid handling solutions, and detection instruments.
Tecan Group AG, a leading Swiss biotechnology company, boasts a rich history and an impressive background. Founded in 1980, Tecan has been at the forefront of developing state-of-the-art laboratory instruments and solutions. With a global presence in over 52 countries, Tecan specializes in providing automated workflows for life science research, diagnostics, and clinical laboratories. This innovative company has consistently introduced groundbreaking technologies, such as robotics and liquid handling platforms, to enable faster and more efficient scientific discovery. With a relentless commitment to excellence, Tecan has earned a stellar reputation as a trusted partner in advancing scientific research and improving healthcare worldwide.
Tecan Group AG, a renowned biotechnology company, has achieved significant milestones over the years. One notable achievement is its establishment as a global leader in automated laboratory instruments and solutions. With its cutting-edge technology, Tecan has revolutionized the field of life sciences and diagnostics. The company's innovative products have enabled researchers and scientists worldwide to perform complex tasks efficiently and accurately. Moreover, Tecan has consistently expanded its product portfolio, introducing advanced platforms and solutions that cater to various scientific needs. This dedication to innovation and customer satisfaction has propelled Tecan Group AG to the forefront of the biotechnology industry, making it a trusted name among researchers and laboratories globally.
Tecan Group AG, a global leader in laboratory automation and detection solutions, has a strong presence in various countries and regions worldwide. The company operates in more than 50 countries, spanning North America, Europe, Asia-Pacific, and Latin America. With its headquarters in Switzerland, Tecan Group AG has established itself as a leading provider of innovative laboratory instruments and consumables across the globe.
Tecan Group AG represents a set of core values and a strong corporate philosophy. They prioritize innovation, quality, and customer focus in all their operations. With a commitment to excellence, Tecan strives to deliver cutting-edge solutions and services to their clients. Their corporate philosophy centers around fostering partnerships, integrity, and sustainability. Through continuous improvement and a dedication to their mission, Tecan aims to create long-term value for their shareholders and stakeholders. This Swiss-based company has a renowned reputation in the life sciences industry, constantly pushing boundaries and driving progress with their advanced laboratory automation and detection solutions.
Analysts currently set an average price target of 185.49 CHF for the Tecan Group stock (median: 168.30 CHF), implying -21.7 % versus the latest price. The consensus is based on 13 analyst ratings.
13 analysts currently rate the Tecan Group stock: 8 recommend buying, 5 holding and 0 selling. For 2026, analysts expect Tecan Group to generate revenue of 886.83 M CHF and earnings per share of 6.41 CHF.
Converted at the current exchange rate, the Tecan Group share trades at 254.21 EUR (237.00 CHF).
The Tecan Group share (TECN.SW) is listed on 6 stock exchanges, including: London (0QLN.L), SIX (Zürich) (TECN.SW), Frankfurt (TEN.F), München (TEN.MU).
The Tecan Group AG is a globally leading company in the development, manufacturing, and marketing of laboratory automation solutions for the life science industry. The company's business model is based on the combination of high-quality instruments, software, and consumables to provide automation solutions for research institutions, diagnostic and pharmaceutical companies, as well as clinical and forensic analysis. Tecan consists of two business sectors: Life Sciences and Partnering Business. The Life Sciences sector includes the development and manufacturing of Tecan products for laboratory automation. This includes, for example, analysis and diagnostic devices, pipetting robots, extraction solutions, and software for laboratory automation. The Partnering Business involves the production of OEM instruments for partner companies, as well as collaboration with customers and partners in the development of custom solutions. Tecan's core product is the so-called Fluent Liquid Handling Workflow. This workflow accelerates the automation of laboratory tests in pharmaceutical companies, diagnostic and research institutions. The workflow consists of a combination of automated pipettes, sample handling, microplate management systems, and data management software. Tecan's focus is on automating workflows and improving efficiency in laboratory analysis. This is achieved by providing solutions for workflow and process automation, which in turn save time and resources and enhance accuracy in science. Another product portfolio of Tecan is its consumables. These are sold under the brand names Tecan, Cavro, TECAN PURE, and TECAN SELECT, and include tips, racks, plates, and seals that are tailored to the company's instruments. The consumables are offered in various sizes and formats and are suitable for a variety of applications in the life science industry. To provide the best possible service to its customers, Tecan maintains a large network of sales and service organizations in Europe, America, and Asia. These organizations offer comprehensive technical support and advice in solving problems that may occur during the operation of Tecan instruments. Overall, Tecan's business model is focused on providing effective and automated solutions for laboratory automation. The company is committed to continually developing its products to offer customers unique customer-oriented services that help them make their work more effective and efficient.
The expected revenue of Tecan Group is 886.83 M CHF. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Tecan Group is 81.24 M CHF. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Tecan Group is currently 36.95. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Tecan Group stock.
The price-to-sales ratio (P/S) of Tecan Group is currently 3.39. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Tecan Group stock.
The Eulerpool Quality Score for Tecan Group is 2/10.
The ISIN of Tecan Group is CH0012100191. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Tecan Group is 922557. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Tecan Group is TECN.SW. The ticker symbol is used to trade Tecan Group shares on the stock exchange.
Tecan Group stock
Tecan Group Peer Group
Tecan Group Ticker
Tecan Group FIGI
All fundamentals and in-depth analysis of Tecan Group
Our stock analysis for Tecan Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Tecan Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.